{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cutaneous+Metastasis",
    "query": {
      "condition": "Cutaneous Metastasis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 357,
    "total_pages": 36,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cutaneous+Metastasis&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T17:34:51.968Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07655570",
      "title": "Pilot Study of Ivonescimab in Advanced/Metastatic Cutaneous Angiosarcoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cutaneous Angiosarcoma"
      ],
      "interventions": [
        {
          "name": "Ivonescimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2026-08-19",
      "completion_date": "2029-05-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-25",
      "last_synced_at": "2026-09-24T17:34:51.968Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07655570"
    },
    {
      "nct_id": "NCT00064311",
      "title": "Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Chronic Myeloproliferative Disorders",
        "Gestational Trophoblastic Tumor",
        "Infection",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Testicular Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "ravuconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-06",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2012-03-08",
      "last_synced_at": "2026-09-24T17:34:51.968Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00064311"
    },
    {
      "nct_id": "NCT05479812",
      "title": "Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumor",
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "WTX-124",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Werewolf Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 156,
      "start_date": "2022-05-20",
      "completion_date": "2026-04-22",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-09-24T17:34:51.968Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05479812"
    },
    {
      "nct_id": "NCT00408681",
      "title": "Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia",
        "Adult Acute Lymphoblastic Leukemia in Remission",
        "Adult Acute Myeloid Leukemia in Remission",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Atypical Chronic Myeloid Leukemia, Breakpoint Cluster Region-abl Translocation (BCR-ABL) Negative",
        "Blastic Phase Chronic Myelogenous Leukemia",
        "Childhood Acute Lymphoblastic Leukemia in Remission",
        "Childhood Acute Myeloid Leukemia in Remission",
        "Childhood Chronic Myelogenous Leukemia",
        "Childhood Myelodysplastic Syndromes",
        "Chronic Eosinophilic Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "Chronic Neutrophilic Leukemia",
        "Chronic Phase Chronic Myelogenous Leukemia",
        "de Novo Myelodysplastic Syndromes",
        "Disseminated Neuroblastoma",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Gastrointestinal Complications",
        "Juvenile Myelomonocytic Leukemia",
        "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Noncontiguous Stage II Adult Burkitt Lymphoma",
        "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma",
        "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma",
        "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma",
        "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma",
        "Noncontiguous Stage II Adult Lymphoblastic Lymphoma",
        "Noncontiguous Stage II Grade 1 Follicular Lymphoma",
        "Noncontiguous Stage II Grade 2 Follicular Lymphoma",
        "Noncontiguous Stage II Grade 3 Follicular Lymphoma",
        "Noncontiguous Stage II Mantle Cell Lymphoma",
        "Noncontiguous Stage II Marginal Zone Lymphoma",
        "Noncontiguous Stage II Small Lymphocytic Lymphoma",
        "Poor Prognosis Metastatic Gestational Trophoblastic Tumor",
        "Previously Treated Childhood Rhabdomyosarcoma",
        "Primary Myelofibrosis",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Recurrent Childhood Large Cell Lymphoma",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Small Noncleaved Cell Lymphoma",
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Malignant Testicular Germ Cell Tumor",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent Neuroblastoma",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Ovarian Germ Cell Tumor",
        "Recurrent Small Lymphocytic Lymphoma",
        "Recurrent Wilms Tumor and Other Childhood Kidney Tumors",
        "Recurrent/Refractory Childhood Hodgkin Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Hairy Cell Leukemia",
        "Relapsing Chronic Myelogenous Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndromes",
        "Splenic Marginal Zone Lymphoma",
        "Stage I Multiple Myeloma",
        "Stage II Multiple Myeloma",
        "Stage II Ovarian Epithelial Cancer",
        "Stage III Adult Burkitt Lymphoma",
        "Stage III Adult Diffuse Large Cell Lymphoma",
        "Stage III Adult Diffuse Mixed Cell Lymphoma",
        "Stage III Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage III Adult Hodgkin Lymphoma",
        "Stage III Adult Immunoblastic Large Cell Lymphoma",
        "Stage III Adult Lymphoblastic Lymphoma",
        "Stage III Chronic Lymphocytic Leukemia",
        "Stage III Grade 1 Follicular Lymphoma",
        "Stage III Grade 2 Follicular Lymphoma",
        "Stage III Grade 3 Follicular Lymphoma",
        "Stage III Malignant Testicular Germ Cell Tumor",
        "Stage III Mantle Cell Lymphoma",
        "Stage III Marginal Zone Lymphoma",
        "Stage III Multiple Myeloma",
        "Stage III Ovarian Epithelial Cancer",
        "Stage III Small Lymphocytic Lymphoma",
        "Stage IIIA Breast Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IV Adult Burkitt Lymphoma",
        "Stage IV Adult Diffuse Large Cell Lymphoma",
        "Stage IV Adult Diffuse Mixed Cell Lymphoma",
        "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage IV Adult Hodgkin Lymphoma",
        "Stage IV Adult Immunoblastic Large Cell Lymphoma",
        "Stage IV Adult Lymphoblastic Lymphoma",
        "Stage IV Breast Cancer",
        "Stage IV Chronic Lymphocytic Leukemia",
        "Stage IV Grade 1 Follicular Lymphoma",
        "Stage IV Grade 2 Follicular Lymphoma",
        "Stage IV Grade 3 Follicular Lymphoma",
        "Stage IV Mantle Cell Lymphoma",
        "Stage IV Marginal Zone Lymphoma",
        "Stage IV Ovarian Epithelial Cancer",
        "Stage IV Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "lithium carbonate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2006-06",
      "completion_date": "2015-05-01",
      "has_results": true,
      "last_update_posted_date": "2017-03-07",
      "last_synced_at": "2026-09-24T17:34:51.968Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00408681"
    },
    {
      "nct_id": "NCT05859074",
      "title": "A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cutaneous Squamous Cell Carcinoma",
        "SCC - Squamous Cell Carcinoma",
        "Basal Cell Carcinoma",
        "BCC",
        "BCC - Basal Cell Carcinoma",
        "Melanoma",
        "Merkel Cell Carcinoma",
        "Sebaceous Carcinoma",
        "Extramammary Paget Disease",
        "Kaposi Sarcoma",
        "Head and Neck Squamous Cell Carcinoma",
        "HNSCC",
        "Adnexal Carcinoma",
        "Angiosarcoma",
        "Cutaneous Neoplasm",
        "Advanced Cancer",
        "Metastatic Cancer",
        "Refractory Cancer",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "MQ719",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2023-05-04",
      "completion_date": "2028-05-04",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-09-24T17:34:51.968Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05859074"
    },
    {
      "nct_id": "NCT00453050",
      "title": "Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma (Skin)",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "imiquimod",
          "type": "DRUG"
        },
        {
          "name": "indocyanine green solution",
          "type": "DRUG"
        },
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "immunologic technique",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Oklahoma",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2006-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-05-06",
      "last_synced_at": "2026-09-24T17:34:51.968Z",
      "location_count": 1,
      "location_summary": "Tulsa, Oklahoma",
      "locations": [
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00453050"
    },
    {
      "nct_id": "NCT05585320",
      "title": "A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Pancreatic Adenocarcinoma",
        "Malignant Melanoma (Cutaneous)",
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "IMM-1-104 Monotherapy (Treatment Group A)",
          "type": "DRUG"
        },
        {
          "name": "IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B)",
          "type": "DRUG"
        },
        {
          "name": "IMM-1-104 + modified FOLFIRINOX (Treatment Group C)",
          "type": "DRUG"
        },
        {
          "name": "IMM-1-104 + dabrafenib (Treatment Group D)",
          "type": "DRUG"
        },
        {
          "name": "IMM-1-104 + pembrolizumab (Treatment Group E)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immuneering Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 209,
      "start_date": "2022-10-31",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2025-09-02",
      "last_synced_at": "2026-09-24T17:34:51.968Z",
      "location_count": 20,
      "location_summary": "Scottsdale, Arizona • Duarte, California • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05585320"
    },
    {
      "nct_id": "NCT02652455",
      "title": "Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Melanoma (Skin)",
        "Skin Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Surgery to Remove Tumor for Growth of TIL",
          "type": "PROCEDURE"
        },
        {
          "name": "CD137",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "TIL Infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Interleukin-2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2016-03-08",
      "completion_date": "2020-08-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-19",
      "last_synced_at": "2026-09-24T17:34:51.968Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02652455"
    },
    {
      "nct_id": "NCT02304458",
      "title": "Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Melanoma",
        "Recurrent Neuroblastoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Osteosarcoma",
        "Recurrent Rhabdomyosarcoma",
        "Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Hodgkin Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Melanoma",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Osteosarcoma",
        "Refractory Rhabdomyosarcoma",
        "Stage III Cutaneous Melanoma AJCC v7",
        "Stage IIIA Cutaneous Melanoma AJCC v7",
        "Stage IIIB Cutaneous Melanoma AJCC v7",
        "Stage IIIC Cutaneous Melanoma AJCC v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "12 Months to 30 Years"
      },
      "enrollment_count": 140,
      "start_date": "2015-03-30",
      "completion_date": "2023-03-31",
      "has_results": true,
      "last_update_posted_date": "2023-10-17",
      "last_synced_at": "2026-09-24T17:34:51.968Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02304458"
    },
    {
      "nct_id": "NCT04789668",
      "title": "Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Hormone Receptor Positive Breast Adenocarcinoma",
        "Metastatic Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Neoplasm in the Brain",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Melanoma",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Prognostic Stage IV Breast Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Bintrafusp Alfa",
          "type": "DRUG"
        },
        {
          "name": "Pimasertib",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2021-01-15",
      "completion_date": "2023-12-08",
      "has_results": true,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-09-24T17:34:51.968Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04789668"
    }
  ]
}